AIM BREAKFAST – 9th November 2016
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 993
Total number of AIM Companies trading: 971*
* As at 08 November 2016
Dish of the Day:
No AIM Joiners Today
No AIM Joiners Today
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
Set Menu ISDX Growth:
Total number of ISDX Growth Market Companies (Incl Susp): *
Total number of ISDX Growth Market Companies trading: *
* As at 08 November 2016
Dish of the Day:
Off the Menu:
What’s Cooking in the IPO Kitchen?
Diversified Gas & Oil—The US based gas and oil producer is seeking a December AIM quoting to raise circa $60m
FreeAgent—Schedule one now out from the provider of accounting software to small businesses. Date and quantum of raise still to be disclosed.
Civitas Social Housing –Intention to float on Main Market from the first REIT to be listed on the London Stock Exchange offering pure play exposure to social housing
Karelian Diamond Resources (KDR.L) 0.58p £1.4m
The diamond exploration company focused on Finland, has received results and a report from the Geological Survey of Finland, commissioned by the Company. New Kimberlite Boulder Discovery 2.5km SW of Lahtojoki Diamond Deposit. Further Six Kimberlite Boulders Found 500m from First Discovery. This raises the possibility of another diamondiferous kimberlite close to the Lahtojoki deposit potentially increasing the financial and technical attractiveness of the Lahtojoki diamond deposit.
DODS Group (DODS.L) 13.63p £46.4m
The parliamentary communications and political information Group has reported H1 Sep 16 results. Revenue up 5% to £9.74m. EPS of 0.34p vs 0.2p. Cash of £7.9m from £7m after £2.6m of investment spend. New products include the Dods People App and Political Risk Reports . FY Mar17E revenue of £20.6m, PBT of £2.2m and EPS of 0.83p. 16.4x PE.
Stellar Diamonds (STEL.L) 7.22p £2.29m
The diamond development company focused on West Africa, has signed joint venture agreements with Citigate Commodities Trading, a Dubai based commodities group, over the Company’s Baoulé kimberlite project in Guinea and two earlier stage exploration licences in western Liberia. The Company currently has a 75% interest in the Baoulé Project and a 100% interest in the Liberia Project. Baoulé earn in of up to 75% by Citigate up to and including pre-feasibility study. Liberia up to 85%. Three phases totalling over $6m spend.
SCISYS (SSY.L) 83.5p £24.3m
The supplier of bespoke software systems, IT-based solutions and support services to the media, space, government, defence and environment sectors, has signed a contract with WorldVu Satellites, Ltd. dba OneWeb, a global satellite communications service provider who is building the world’s largest satellite constellation that will provide connectivity to billions of people globally. SCISYS will deliver satellite mission-planning software based on its PLENITER®. FYDec16E £41.5m rev, £2.7m PBT
Prime People (PRP.L) 97.5p £11.97m
HYSep16E results from the global specialist recruitment business. Net Fee Income (NFI) in the period for the Group was £6.33m which is a 1.87% increase on last year. H1 showed strong NFI performances in the Hong Kong and Singapore business units. In Asia NFI increased by 36.84% to £2.60m and in the UK NFI decreased by 12.82% to £3.40m. PBT decreased to £0.76m (2015: £1.06m). Outlook—Reasonable hopes UK will perform in line with H1. Sentiment in UK property improved but uncertainty remains. Increased opportunities in Asia. No FY market forecasts.
Taptica International (TAP.L) 147.5p £92.2m
FYDec16 trading update from global end-to-end mobile advertising platform for advertising agencies and brands. As a result of strong momentum the Company now expects to report FY 2016 revenues ahead of market expectations at approximately $120m, up 55% YoY. The Company expects adjusted EBITDA for FY 2016 to be significantly higher than market expectations at approximately $22.5m, representing a year-on-year growth in adjusted EBITDA of over 200%. Some uncertainty ahead as mobile enters a new phase of maturity.
Oxford Pharmasciences (OXP.L) 2p £24.1m
The specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take has updated on its R&D pipeline. New patent filing for OXPzeroTM technology platform (Release platform for Ibuprofen and Naproxen). Progressing to phase 1. Also looking at applications for Aspirin and developing new statin formulation. Well funded with cash of £22.6m as at 31 October 2016.
Providence Resources (PVR.L) 10.25p £61.26m
Update from the Irish based Oil and Gas Exploration Company regarding permission to appeal the Court of Appeal decision handed down on April 13, 2016 which pertains to the prior litigation between the Company and Transocean Drilling U.K. Limited. The Supreme Court ordered that permission to appeal be refused as the appeal does not raise a point of law of general public importance. Following the initial judgement the Company paid out $6.15m .
ECR Minerals (ECR.L) 0.004p £1.16m
Update from the Victorian Gold Projects, Australia. The Company has decided to prioritise drilling of selected targets at ECR’s wholly owned Avoca and Bailieston gold projects. Proposed reverse circulation drilling programme of approximately 550 metres to test prospects within the Byron area at the Bailieston project (EL5433). Bailieston programme anticipated to commence by early 2017. Re-evaluation of the exploration potential at Avoca – now targeting nine high-grade hard-rock targets. Continuing to progress applications for two new Exploration Licences in Victoria.
Pacific Industrial & Logistics REIT (PILR.L) 107p £11.04m
The specialist Real Estate Investment Trust focused on smaller lot size industrial and logistics properties, has announced a placing priced at £1 raising gross proceeds of £11.1m. The proceeds will primarily be used to fund future acquisitions and reduce gearing to c.45%. Appointment of Mr. Nigel Rich CBE as non-executive chairman, formerly Chairman of Segro plc, and Mr. Mark Johnson, the CEO and co-founder of Pacific Investments with Sir John Beckwith, as a non-executive director, both with effect from 1 January 2017.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.